度他雄胺结构式
|
常用名 | 度他雄胺 | 英文名 | Dutasteride |
|---|---|---|---|---|
| CAS号 | 164656-23-9 | 分子量 | 528.530 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 620.3±55.0 °C at 760 mmHg | |
| 分子式 | C27H30F6N2O2 | 熔点 | 242-250ºC | |
| MSDS | 中文版 美版 | 闪点 | 329.0±31.5 °C |
度他雄胺用途Dutasteride (GG745)是5α还原酶同工酶抑制剂,还可能因其结构域DHT相似对雄激素受体(AR)产生脱靶效应。 |
| 中文名 | 度他雄胺 |
|---|---|
| 英文名 | dutasteride |
| 英文别名 | 更多 |
| 描述 | Dutasteride (GG745)是5α还原酶同工酶抑制剂,还可能因其结构域DHT相似对雄激素受体(AR)产生脱靶效应。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 1.3±0.1 g/cm3 |
|---|---|
| 沸点 | 620.3±55.0 °C at 760 mmHg |
| 熔点 | 242-250ºC |
| 分子式 | C27H30F6N2O2 |
| 分子量 | 528.530 |
| 闪点 | 329.0±31.5 °C |
| 精确质量 | 528.221130 |
| PSA | 58.20000 |
| LogP | 5.61 |
| 外观性状 | 白色结晶固体 |
| 蒸汽压 | 0.0±1.8 mmHg at 25°C |
| 折射率 | 1.523 |
| 储存条件 | -20°C Freezer |
| 水溶解性 | DMSO: soluble2mg/mL, clear |
| 危险品运输编码 | NONH for all modes of transport |
|---|---|
| 海关编码 | 2942000000 |
| 海关编码 | 2933990090 |
|---|---|
| 中文概述 | 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro
J. Steroid Biochem. Mol. Biol. 144 Pt B , 436-44, (2014) • Dutasteride and abiraterone were evaluated for inhibition of steroidogenesis. • Bypass mechanisms arise in the presence of abiraterone to form DHT. • Dutasteride inhibits T and DHT effectively in vi... |
|
|
Preparation of microcapsules with the evaluation of physicochemical properties and molecular interaction.
Arch. Pharm. Res. 37(12) , 1570-7, (2014) The objective of this study was to prepare and characterize dutasteride (a hydrophobic model drug) microcapsules using ethyl cellulose as a capsule shell polymer with different drug/polymer ratios of ... |
|
|
Long term effectiveness on prescribing of two multifaceted educational interventions: results of two large scale randomized cluster trials.
PLoS ONE 9(10) , e109915, (2014) Information on benefits and risks of drugs is a key element affecting doctors' prescribing decisions. Outreach visits promoting independent information have proved moderately effective in changing pre... |
| (5a,17b)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide |
| (5α,17β)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide |
| Avodart |
| Duagen |
| α,α,α,α',α',α'-Hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide |
| Dutasteride |
| (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-[2,5-Bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide |
| 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- |
| a,a,a,a',a',a'-Hexafluoro-3-oxo-4-aza-5a-androst-1-ene-17b-carboxy-2',5'-xylidide |